EDGEWISE THERAPEUTICS INC's ticker is EWTX and the CUSIP is 28036F105. A total of 95 filers reported holding EDGEWISE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $560,364 | +21.6% | 31,114 | +23.1% | 0.00% | – |
| Q1 2024 | $460,998 | +106.5% | 25,274 | +23.8% | 0.00% | – |
| Q4 2023 | $223,285 | +84.7% | 20,410 | -3.3% | 0.00% | – |
| Q3 2023 | $120,886 | -13.0% | 21,097 | +17.7% | 0.00% | – |
| Q2 2023 | $138,880 | -11.8% | 17,920 | -24.1% | 0.00% | – |
| Q1 2023 | $157,392 | +5.8% | 23,597 | +41.8% | 0.00% | – |
| Q4 2022 | $148,735 | +25.0% | 16,637 | +37.9% | 0.00% | – |
| Q3 2022 | $119,000 | +6.2% | 12,064 | -14.2% | 0.00% | – |
| Q2 2022 | $112,000 | -47.7% | 14,055 | -36.1% | 0.00% | – |
| Q1 2022 | $214,000 | -42.8% | 21,996 | -10.2% | 0.00% | – |
| Q4 2021 | $374,000 | +206.6% | 24,494 | +232.3% | 0.00% | – |
| Q3 2021 | $122,000 | -21.8% | 7,370 | +0.3% | 0.00% | – |
| Q2 2021 | $156,000 | – | 7,345 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,553,661 | $27,981,435 | 34.02% |
| Novo Holdings A/S | 6,344,430 | $114,263,184 | 6.63% |
| Orbimed Advisors | 15,021,721 | $270,541,195 | 5.34% |
| TCG Crossover Management, LLC | 2,272,728 | $40,931,831 | 4.27% |
| Frazier Life Sciences Management, L.P. | 3,731,067 | $67,196,517 | 3.14% |
| Cormorant Asset Management, LP | 3,006,534 | $54,147,677 | 3.13% |
| Opaleye Management Inc. | 580,000 | $10,445,800 | 2.39% |
| RA Capital Management | 8,909,091 | $160,452,729 | 2.12% |
| VR Adviser, LLC | 1,818,182 | $32,745,458 | 2.08% |
| MPM BioImpact LLC | 740,661 | $13,339,305 | 2.07% |